Brind.

The FDA's GRAS status allows supplements to bypass full review, a point targeted by Kennedy and analyzed by experts like Professor Cohen, involving Calley Means and Harvard Medical School.

Steady: 0 in the last 7 days Updated oct 23

The latest in this situation

  1. Advocacy for mandatory UPF labeling challenges industry claims regarding FDA standards.

How it started

3 reports, 3 independent, last reported Oct 23. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

The FDA's GRAS status allows supplements to bypass full review, a point targeted by Kennedy and analyzed by experts like Professor Cohen, involving Calley Means and Harvard Medical School.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Advocacy for mandatory UPF labeling challenges industry claims regarding FDA standards.1 source
  2. Cohen critiques FDA testing standards regarding product review.1 source
  3. APA research informs expert critique of the institutional review process regarding GRS's status.Sub-event
  4. Kennedy targets the FDA's GRAS loophole allowing supplements to bypass full review, with expert analysis from Harvard Medical School.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped